Clinical Trial Update: Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Clofarabine, Cytarabine and Mitoxantrone (CLAM) in relapsed or refractory acute myeloid leukemia is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Clofarabine, Cytarabine and Mitoxantrone (CLAM)

Snippet

Sponsor: The University of Hong Kong | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED